New drug combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT07355010
First seen Jan 21, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tests two new drug combinations given before surgery for people with advanced ovarian cancer that cannot be fully removed right away. The goal is to shrink the tumor enough to allow successful surgery. About 104 participants with a specific type of ovarian cancer (BRCA wild-type) will receive either fluzoparib plus famitinib or fluzoparib plus SHR-1701. The study measures how well the tumors respond and how safe the treatments are.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.